Inhibrx Biosciences, Inc. Cash Flow Statement

Cash Flow Statement Dec2023 Dec2024
Operating Activities
Net Income -239.73M1687.57M
Share-based Compensation 24.85M58.52M
Gains from Investment Securities 1.63M3.67M
Cash from Operations -193.31M-194.41M
Depreciation, Depletion & Amortization
Amortization of Deferred Charges 4.90M2.06M
Depreciation & Amortization (CF) 1.19M2.29M
Change in Working Capital
Change in Receivables 0.54M-0.38M
Change in Account Payables 2.11M17.90M
Change in Accured Expenses 26.07M35.88M
Investing Activities
Capital Expenditures 4.59M2.60M
Cash from Investing Activities -4.59M-2.60M
Financing Activities
Change in Capital Stock
Shares Issued 200.00M71.68M
Misc.
Cash from Financing Activities 201.96M71.68M
Change in Cash 4.06M-125.33M
Free Cash Flow -197.90M-197.01M
Net Cash Flow 4.06M-125.33M